Oragenics (Oragenics) Scaled Net Operating Assets : 0.14 (As of Mar. 2024)

View and export this data going back to 2003. Start your Free Trial

What is Oragenics Scaled Net Operating Assets?

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

Oragenics's operating assets for the quarter that ended in Mar. 2024 was $1.46 Mil. Oragenics's operating liabilities for the quarter that ended in Mar. 2024 was $0.78 Mil. Oragenics's Total Assets for the quarter that ended in Dec. 2023 was $4.97 Mil. Therefore, Oragenics's scaled net operating assets (SNOA) for the quarter that ended in Mar. 2024 was 0.14.

Oragenics Scaled Net Operating Assets Historical Data

The historical data trend for Oragenics's Scaled Net Operating Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Oragenics Scaled Net Operating Assets Chart

Oragenics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Scaled Net Operating Assets

Get a 7-Day Free Trial

0.01

0.08

Oragenics Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Scaled Net Operating Assets	Get a 7-Day Free Trial															0.10	0.09	0.15	-	0.14

Competitive Comparison of Oragenics's Scaled Net Operating Assets

For the Biotechnology subindustry, Oragenics's Scaled Net Operating Assets, along with its competitors' market caps and Scaled Net Operating Assets data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Oragenics's Scaled Net Operating Assets Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Oragenics's Scaled Net Operating Assets distribution charts can be found below:

* The bar in red indicates where Oragenics's Scaled Net Operating Assets falls into.

Oragenics Scaled Net Operating Assets Calculation

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

Oragenics's Scaled Net Operating Assets (SNOA) for the fiscal year that ended in Dec. 2023 is calculated as

	Scaled Net Operating Assets (SNOA)		(A: Dec. 2023 )
=	(Operating Assets (A: Dec. 2023 )	-	Operating Liabilities (A: Dec. 2023 ))	/	Total Assets (A: Dec. 2022 )
=	(1.482	-	1.475)	/	14.758
=	0.00

where

	Operating Assets		(A: Dec. 2023 )
=	Total Assets	-	Cash, Cash Equivalents, Marketable Securities
=	4.966	-	3.484
=	1.482

	Operating Liabilities		(A: Dec. 2023 )
=	Total Liabilities	-	Long-Term Debt & Capital Lease Obligation	-	Short-Term Debt & Capital Lease Obligation
=	1.798	-	0	-	0.323
=	1.475

Oragenics's Scaled Net Operating Assets (SNOA) for the quarter that ended in Mar. 2024 is calculated as

	Scaled Net Operating Assets (SNOA)		(Q: Mar. 2024 )
=	(Operating Assets (Q: Mar. 2024 )	-	Operating Liabilities (Q: Mar. 2024 ))	/	Total Assets (Q: Dec. 2023 )
=	(1.462	-	0.782)	/	4.966
=	0.14

where

	Operating Assets		(Q: Mar. 2024 )
=	Total Assets	-	Cash, Cash Equivalents, Marketable Securities
=	3.534	-	2.072
=	1.462

	Operating Liabilities		(Q: Mar. 2024 )
=	Total Liabilities	-	Long-Term Debt & Capital Lease Obligation	-	Short-Term Debt & Capital Lease Obligation
=	0.909	-	0	-	0.127
=	0.782

Oragenics Scaled Net Operating Assets Related Terms

Thank you for viewing the detailed overview of Oragenics's Scaled Net Operating Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

Oragenics (Oragenics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oragenics Inc (AMEX:OGEN) » Definitions » Scaled Net Operating Assets

Comparable Companies

Traded in Other Exchanges

0A64:UK

Address

4902 Eisenhower Boulevard, Suite 125, Tampa, FL, USA, 33634

Website

https://www.oragenics.com

Oragenics Inc is engaged in research and the development of potential therapies to fight infectious diseases including coronaviruses and multidrug-resistant organisms. Its product (NT-CoV2-1) is an intranasal vaccine candidate to prevent coronavirus disease ("COVID-19") from the SARS-CoV-2 virus and variants thereof. Its focus on developing vaccines and novel antibiotics It is also developing a Terra CoV-2 immunization product candidate to combat the novel coronavirus.

Executives

Fred Telling	director	501 ELLIOTT AVE. W., SUITE 400, SEATTLE WA 98119
John P Gandolfo	director	62 TERRACE ROAD, WAYNE NJ 07470
Cassidy Bruce A. Sr.	director	C/O LOOP MEDIA, 700 N CENTRAL AVENUE, SUITE 430, GLENDALE CA 91203
Janet Huffman	officer: CFO, Secretary and Treasurer	5317 FRUITVILLE RD SUITE 6, SARASOTA FL 34232
Robert C Koski	director, 10 percent owner	1500 W UNIVERSITY PARKWAY, SARASOTA FL 34243
Michael O'keefe Sullivan	officer: CFO, Secretary and Treasurer	3000 BAYPORT DRIVE, SUITE 685, TAMPA FL 33607
Joseph Hernandez	10 percent owner	C/O MICROLIN BIO, INC., NEW YORK NY 10022
Kimberly M Murphy	director	101 EAST KENNEDY BLVD., SUITE 2800, TAMPA FL 33602
Koski Family Lp	10 percent owner	1500 W UNIVERSITY PARKWAY, SARASOTA FL 34243
Randal J Kirk	10 percent owner	1881 GROVE AVENUE, RADFORD VA 24141
Alan Joslyn	director, officer: CEO and President	39 OLD RIDGEBURY ROAD, DANBURY CT 06810
Charles L Pope	director	4902 EISENHOWER BOULEVARD, TAMPA FL 33634
Christine L Koski	director, 10 percent owner	1500 WEST UNIVERSITY PARKWAY, SARASOTA FL 34243
Beverly Koski	10 percent owner
Thomas L Koski	10 percent owner